ADHD is both one of the most common and one of the most misunderstood childhood conditions. At one extreme, it is over-attributed – every energetic, impulsive child is given the label. At the other, it is under-recognised in girls, in children with the inattentive presentation (who may be dreamy and academically struggling without any hyperactivity), and in children from families or schools with limited knowledge of the condition.
Getting the diagnosis right matters because the right support – which is specific, structured, and multi-component – produces substantially better outcomes than either no support or the wrong support. And ADHD without support has real consequences: educational underperformance, relationship difficulties, low self-esteem, and increased risk of mental health conditions are all significantly more common in unsupported children with ADHD than in those who receive appropriate help.
Healthbooq (healthbooq.com) covers neurodevelopmental conditions in children.
What ADHD Is
ADHD is a neurodevelopmental condition characterised by persistent, pervasive difficulties with attention regulation, activity level control, and impulse control. The DSM-5 describes three presentations:
Predominantly inattentive presentation: difficulty sustaining attention, easily distracted, forgetful, losing things, difficulty organising tasks, not following through on instructions, appearing not to listen when spoken to directly. This presentation is more common in girls and is more often missed because it does not produce the classroom disruption associated with hyperactive ADHD.
Predominantly hyperactive-impulsive presentation: difficulty staying seated, running or climbing excessively in inappropriate situations, talking excessively, blurting out answers before questions are complete, difficulty waiting for turns, interrupting. This presentation is more visible and is more commonly referred for assessment in primary school years.
Combined presentation: both inattentive and hyperactive-impulsive features. Most common presentation in clinical settings.
For diagnosis, symptoms must: have been present for at least 6 months; be developmentally inappropriate (not merely consistent with the child's age); be present in at least two settings (home and school); and cause significant functional impairment.
The Neuroscience of ADHD
ADHD is associated with differences in the dopaminergic and noradrenergic systems that regulate prefrontal cortex function. The prefrontal cortex (PFC) is responsible for executive functions: working memory, inhibitory control, sustained attention, and planning. Research by Russell Barkley at the Medical University of South Carolina, and neuroimaging studies by Phil Shaw at the National Institutes of Health (which found a 3-year delay in cortical maturation in children with ADHD, published in PNAS in 2007), has established ADHD as a condition of delayed and different neurological development rather than wilful behaviour.
The delay in cortical maturation has practical implications for parenting and teaching: many children with ADHD function emotionally and behaviourally at around 3-5 years younger than their chronological age in terms of self-regulation.
Assessment and Diagnosis
Assessment in the UK is carried out by CAMHS, community paediatricians, or (for adolescents) by adult psychiatry services with a CAMHS interface. It involves: a structured clinical interview with parents and child; standardised questionnaires completed by parents and teachers; review of educational information; and consideration of co-occurring conditions.
There is no biological test for ADHD. The diagnosis is clinical, based on the pattern and impact of symptoms. Common co-occurring conditions include anxiety (50%), depression (30%), learning differences (dyslexia, dyspraxia), sleep disorders, and autism.
Treatment
For children under 5: parent training in ADHD-specific behaviour management is the first-line treatment (NICE NG87). Medication is not recommended routinely for under-5s.
For school-age children (5-17) with moderate-to-severe ADHD:
Parent training: structured programmes (such as the Incredible Years, Stepping Stones Triple P, or New Forest Parenting Programme, which is ADHD-specific) teach parents ADHD-informed behaviour management strategies. The evidence base is strong.
Medication: methylphenidate (Ritalin, Concerta) is the first-line stimulant medication, increasing dopamine and noradrenaline availability in the prefrontal cortex. It is effective in approximately 70% of children. Lisdexamfetamine (Vyvanse) and dexamfetamine are second-line stimulants; atomoxetine (a non-stimulant noradrenaline reuptake inhibitor) is used when stimulants are not tolerated or are contraindicated.
School-based strategies: preferential seating, task chunking, use of planners and visual schedules, movement breaks, and reduced task demand without reducing expectations are practical accommodations that make a meaningful difference.
ADHD UK (adhduk.co.uk) and ADDISS (addiss.co.uk) provide further resources for families.
Key Takeaways
ADHD (Attention Deficit Hyperactivity Disorder) is one of the most common neurodevelopmental conditions of childhood, affecting approximately 5% of children and adolescents in the UK. It is characterised by persistent inattention, hyperactivity, and impulsivity that is developmentally inappropriate and causes functional impairment across settings. There are three presentations: predominantly inattentive, predominantly hyperactive-impulsive, and combined. NICE guideline NG87 recommends that for children under 5, parent training programmes are first-line treatment before medication is considered. For school-age children with moderate-to-severe ADHD, medication (typically methylphenidate) combined with parent training and school-based strategies provides the best outcomes. ADHD frequently co-occurs with dyslexia, DCD, autism, anxiety, and sleep difficulties.
